scholarly journals Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance.

1980 ◽  
Vol 17 (4) ◽  
pp. 658-662 ◽  
Author(s):  
G L Mandell ◽  
D R Moorman
2010 ◽  
Vol 363 (11) ◽  
pp. 1005-1015 ◽  
Author(s):  
Catharina C. Boehme ◽  
Pamela Nabeta ◽  
Doris Hillemann ◽  
Mark P. Nicol ◽  
Shubhada Shenai ◽  
...  

Molecules ◽  
2021 ◽  
Vol 26 (6) ◽  
pp. 1758
Author(s):  
Urszula Wójcik-Bojek ◽  
Joanna Rywaniak ◽  
Przemysław Bernat ◽  
Anna Podsędek ◽  
Dominika Kajszczak ◽  
...  

Staphylococcus aureus is still one of the leading causes of both hospital- and community-acquired infections. Due to the very high percentage of drug-resistant strains, the participation of drug-tolerant biofilms in pathological changes, and thus the limited number of effective antibiotics, there is an urgent need to search for alternative methods of prevention or treatment for S. aureus infections. In the present study, biochemically characterized (HPLC/UPLC–QTOF–MS) acetonic, ethanolic, and water extracts from fruits and bark of Viburnum opulus L. were tested in vitro as diet additives that potentially prevent staphylococcal infections. The impacts of V. opulus extracts on sortase A (SrtA) activity (Fluorimetric Assay), staphylococcal protein A (SpA) expression (FITC-labelled specific antibodies), the lipid composition of bacterial cell membranes (LC-MS/MS, GC/MS), and biofilm formation (LIVE/DEAD BacLight) were assessed. The cytotoxicity of V. opulus extracts to the human fibroblast line HFF-1 was also tested (MTT reduction). V. opulus extracts strongly inhibited SrtA activity and SpA expression, caused modifications of S. aureus cell membrane, limited biofilm formation by staphylococci, and were non-cytotoxic. Therefore, they have pro-health potential. Nevertheless, their usefulness as diet supplements that are beneficial for the prevention of staphylococcal infections should be confirmed in animal models in the future.


2020 ◽  
Vol 474 (1-2) ◽  
pp. 57-72
Author(s):  
Sulagna Dutta ◽  
Pallav Sengupta ◽  
Emmanuel Izuka ◽  
Ifeanyi Menuba ◽  
Ravindran Jegasothy ◽  
...  

2000 ◽  
Vol 21 (11) ◽  
pp. 745-749 ◽  
Author(s):  
Virginia R. Roth ◽  
Cathryn Murphy ◽  
Trish M. Perl ◽  
Alfred DeMaria ◽  
Annette H. Sohn ◽  
...  

AbstractRoutine use of mupirocin to prevent staphylococcal infections is controversial. We assessed attitudes and practices of healthcare professionals attending the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections regarding mupirocin prophylaxis. Eighty percent of participants did not use mupirocin routinely. At the end of the session, 58% indicated they would consider increased use of mupirocin.


BMJ ◽  
1966 ◽  
Vol 1 (5483) ◽  
pp. 319-322 ◽  
Author(s):  
E. A. Mortimer ◽  
E. Wolinsky ◽  
A. J. Gonzaga ◽  
C. H. Rammelkamp

2015 ◽  
Vol 53 (4) ◽  
pp. 1351-1354 ◽  
Author(s):  
Eiman Mokaddas ◽  
Suhail Ahmad ◽  
Hanaa S. Eldeen ◽  
Noura Al-Mutairi

Among 452 samples that were positive by the Xpert MTB/RIF (Xpert) assay and MGIT 960 system (MGIT), 440 and 10Mycobacterium tuberculosissamples were detected as rifampin susceptible and rifampin resistant, respectively. Two isolates that were rifampin susceptible by the MGIT system were rifampin resistant by the Xpert assay.rpoBsequencing identified a silent (CTG521TTG) mutation in one isolate and a missense (GAC516TAC) mutation in another. The detection of rifampin resistance is imperfect with both the Xpert assay and MGIT system. Any discordant rifampin resistance results should be confirmed by sequencing of therpoBgene.


Sign in / Sign up

Export Citation Format

Share Document